Product Images Dihydroergotamine Mesylate
View Photos of Packaging, Labels & Appearance
- image description - Inner Label a
- image description - Outer Label a
- image description - dihydroergotamine mesylate nasal spray figure 1a
- image description - dihydroergotamine mesylate nasal spray figure 2a
- image description - dihydroergotamine mesylate nasal spray figure 3a
- image description - dihydroergotamine mesylate nasal spray structure a
Product Label Images
The following 6 images provide visual information about the product associated with Dihydroergotamine Mesylate NDC 73352-096 by Trifluent Pharma, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image description - Inner Label a
image description - Outer Label a
This is a description for a medication package containing Dihydroergotamine Mesylate Nasal Spray. This prescription is for nasal use only and should not be injected. The package includes 8 nasal spray bottles and administration instructions. It is important to discard the sprayer with an open vial after treatment completion or within 8 hours. The package insert contains further information and administration instructions. The product should be stored below 25°C (77°F) and should not be refrigerated or frozen.*
image description - dihydroergotamine mesylate nasal spray figure 1a
Estimated Probability of a Patient Responding During the Four Hours Following a Single 2 mg Dose of Dihydroergotamine Mesylate Nasal Spray as a function of the time elapsed since initiation of Studies 1 and 2. The graph shows the response rate over time in hours for patients who received the nasal spray compared to those who received a placebo.*
image description - dihydroergotamine mesylate nasal spray figure 2a
This is information regarding the estimated probability of a patient responding to dihydroergotamine mesylate nasal spray within the first four hours following dosing in Studies 3 and 4. The chart shows the probability of response for the nasal spray compared to a placebo over different time intervals. The study involved a total of 97 patients using the nasal spray and 100 patients using the placebo.*
image description - dihydroergotamine mesylate nasal spray figure 3a
This text provides a visual representation of the estimated probability of patients using additional treatments for migraine over a 24-hour period following the administration of dihydroergotamine mesylate nasal spray (2 mg) or a placebo. The graph shows the likelihood of additional treatment usage at different time points after the first spray, with data for dihydroergotamine mesylate nasal spray (N=308) compared to the placebo group (N=300).*
image description - dihydroergotamine mesylate nasal spray structure a
This text provides relevant information about the chemical composition of Dihydroergotamine mesylate, which is a medication used for treating migraines. The molecular formula (C33H37N505.CH405S) and molecular weight (679.80) are specified.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
